29 September 2016 - CADTH has published its initial recommendtation for Novartis' Afinitor.

CADTH has recommended the reimbursement of everolimus for the treatment of unresectable, locally advanced or metastatic, well differentiated non-functional neuroendocrine tumours of gastro-intestinal or lung origin in adults with progressive disease so long as its cost-effectiveness is improved to an acceptable level.

Read CADTH's initial recommendation for Afinitor